Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Current and Projected Market Size of the Alzheimer’s Disease Diagnostic Market Through 2034?

The market size for diagnosing Alzheimer’s disease has seen a swift expansion in the recent past. From $6.56 billion in 2024, the market is projected to rise to $7.28 billion in 2025, indicating a compound annual growth rate (CAGR) of 11%. The expansion in this historic period has been spurred by factors such as a rising number of Alzheimer’s and dementia cases, growing sensitivity towards early diagnosis for improved management, advancements in imaging technologies like MRI and PET scans, increased research and development investment in neurodegenerative diseases, as well as government-led initiatives and funding dedicated to Alzheimer’s research and diagnostics.

The alzheimer’s disease diagnostic market is all set for rapid growth in the upcoming years, predicted to bolster to a whopping $10.91 billion by 2029, expanding at an impressive compound annual growth rate (CAGR) of 10.7%. This outstanding growth projection for the forecast period can be attributed to several factors such as the development of blood-based biomarkers that enable non-invasive diagnosis, a surge in demand for both personalized medicine and precision diagnostics, merging of AI and machine learning into diagnostic tools to enable early detection, an increase in the adoption of digital health technologies for diagnoses and remote monitoring, and the continued expansion of healthcare infrastructures in emerging markets to improve accessibility. Throughout the forecast period, key trends include the emergence of multi-modal diagnostic approaches that combine imaging, biomarkers, and cognitive tests, an amplified focus on point-of-care diagnostic solutions that deliver quick results, crafting of wearable devices designed for continuous cognitive health monitoring, an upward trend in collaborations between biotech companies and research institutions towards innovation, and a growing prominence in direct-to-consumer genetic testing for Alzheimer’s risk assessment.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Alzheimer’s Disease Diagnostic Market?

The surge in chronic illnesses is anticipated to fuel the expansion of the Alzheimer’s disease diagnostic market in the future. Chronic disease refers to a health issue that lasts more than three months. Several interconnected factors, such as lifestyle decisions, environmental factors, genetic factors, and socioeconomic conditions, contribute to this surge in chronic illnesses. The likelihood of developing Alzheimer’s disease (AD) and other types of dementia is heightened by the existence of chronic conditions like cardiovascular issues, diabetes, and hypertension. For example, the American Heart Association Inc., a volunteer organization based in the U.S., revealed in a report in January 2022 that brain disorders are projected to affect 9.3 million people in the U.S by 2060. At this time, the figure is on a rise with every sixth person around the globe suffering from a brain disease. By 2021, it is projected that 1 billion people across the globe will suffer from brain disorders. Consequently, the uptick in chronic diseases will steer the growth of the Alzheimer’s disease diagnostic market.

Which Segments in the Alzheimer’s Disease Diagnostic Offer the Most Growth?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Alzheimer’s Disease Diagnostic Market?# Market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Alzheimer’s Disease Diagnostic Industry?

Prominent firms engaged in the Alzheimer’s disease diagnostic market are emphasizing cutting-edge developments for a blood-based biomarker test that is likely to streamline Alzheimer’s disease diagnosis, lessen the dependency on more invasive methods, and enhance patient access to expedient therapy. In October 2023, Quanterix, a biotech research firm based in the US, introduced LucentAD p-Tau 217 test, a blood-based Alzheimer’s disease biomarker known for its clinical sensitivity and specificity. Traditional methods for examining cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) or lumbar puncture, are expensive, invasive, and not ubiquitously available. Furthermore, this test integrates Quanterix’s highly sensitive SimoaÒ technology with J&J Innovative Medicine’s thoroughly tested p-Tau 217 antibodies, providing superb accuracy and a more streamlined process.

View the full report here:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What Are the Key Elements That Define the Alzheimer’s Disease Diagnostic Market?

Alzheimer’s disease diagnostics encompass methods and tools used to detect and confirm the presence of Alzheimer’s disease, a progressive neurodegenerative disorder. These diagnostics include cognitive assessments, imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, and biomarker tests analyzing cerebrospinal fluid (CSF) or blood for amyloid-beta and tau proteins.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model